title: [Diagnosis and therapy for neurocognitive disorders in Parkinson's disease].
abstract: In the present review the recent developments in the definitions of neurocognitive disorders associated with Parkinson's disease are summarized including the possibilities for screening and treating. For a long time, the recognition of neurocognitive disorders associated in patients with Parkinson's disease was unsatisfactory due to the heterogeneity of definitions. The recently developed Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) introduced the definitions of mild and major neurocognitive disorders instead of mild cognitive impairment and dementia. The new DSM-5 definitions are clinically well applicable; therefore, the validation of the most frequent screening tests (Mini-Mental State Examination; Addenbrooke's Cognitive Examination; Montreal Cognitive Assessment; Mattis Dementia Rating Scale) is warranted. Based on a Hungarian sample of 295 patients with Parkinson's disease, the cut-off scores having the best discriminative values are highly dependent on education years (Addenbrooke's Cognitive Examination: 0-8 years of education: 82.5 points, 9-12 years of education: 83.5 points, and ≥13 years of education: 84.5 points; Mini-Mental State Examination: 26.5-27.5-28.5 points, Montreal Cognitive Assessment: 23.5-24.5-24.5 points, Mattis Dementia Rating Scale: 138.5-139.5-139.5 points, respectively).
authors.affiliation: Magatartástudományi Intézet, Pécsi Tudományegyetem, Általános Orvostudományi Kar Pécs.
authors.forename: Tivadar
authors.initials: T
authors.lastname: Lucza
authors.forename: Kázmér
authors.initials: K
authors.lastname: Karádi
authors.forename: Sámuel
authors.initials: S
authors.lastname: Komoly
authors.forename: József
authors.initials: J
authors.lastname: Janszky
authors.forename: János
authors.initials: J
authors.lastname: Kállai
authors.forename: Attila
authors.initials: A
authors.lastname: Makkos
authors.forename: Márton
authors.initials: M
authors.lastname: Kovács
authors.forename: Rita
authors.initials: R
authors.lastname: Weintraut
authors.forename: Gabriella
authors.initials: G
authors.lastname: Deli
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Aschermann
authors.forename: Norbert
authors.initials: N
authors.lastname: Kovács
mesh_terms: D002800:Cholinesterase Inhibitors / Q000008:administration & dosage*; D060825:Cognitive Dysfunction / Q000175:diagnosis* / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D003210:Concept Formation; D003704:Dementia / Q000175:diagnosis / Q000628:therapy; D003937:Diagnosis, Differential; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004522:Educational Status; D006801:Humans; D006814:Hungary; D009483:Neuropsychological Tests / Q000592:standards*; D010300:Parkinson Disease / Q000523:psychology*; D040242:Risk Reduction Behavior; D012720:Severity of Illness Index
chemical_list: D002800:Cholinesterase Inhibitors
keywords: Parkinson-kór; Parkinson’s disease; demencia; dementia; enyhe kognitív zavar; mild cognitive impairment; neurocognitive disorder; neurokognitív zavar; screening; szűrés